EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

High-Dose Subcutaneous Administration of Biologics: Overcoming Barriers Through Formulation and Device Innovation

Tarik A Khan, Deep Bhattacharya, Twinkle R Christian, Melissa Holstein, Xiaoqing Hua, Roshan James, Bowen Jiang, Alexander Josowitz, Danielle Laiacona, Shrenik Mehta, Apurva More, Edel Mullen und 5 weitere

Advanced Drug Delivery Reviews · 2026-08 · 235 · 115885

DOI: 10.1016/j.addr.2026.115885 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-08. Verfasst von Tarik A Khan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pharma Technical Development, Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: tarik.khan@roche.com. Hauptthemen laut MEDLINE: Biological Products, Drug Delivery Systems. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic landscape for biologics is rapidly transitioning from intravenous (IV) to subcutaneous (SC) administration, offering significant benefits in cost reduction and patient convenience through enabling treatment in flexible care settings. This shift necessitates patient-centric SC administration solutions. To address this, two primary innovative strategies are emerging: higher concentration formulations and large-volume SC (LVSC) injection/infusion. Ultra-high concentration biologic (UHCB) formulations, defined here as ≥250 g/L, are actively being pursued as suspensions. These UHCB suspension approaches rely on processing methods to entrap biologics within microparticles of a defined particle size (e.g., spray drying, electrospraying, solvent evaporation and dehydration, alginate, crystals). These UHCB suspension formulations are shear-thinning injectable drug product solutions. For LVSC administration, delivery is aided by co-formulating with hyaluronidase and/or utilizing on-body injectors (OBIs), high-volume autoinjectors (HVAI), or other administration equipment that reduces the treatment burden for healthcare professionals, caregivers, and patients. Despite promising preclinical data, the commercial translation of these platforms faces substantial hurdles, including establishing robust aseptic manufacturing processes for suspensions, developing specialized analytical control strategies, ensuring device compatibility (e.g., avoiding needle clogging), and navigating complex regulatory pathways requiring clinical bridging and comparability assessments. Continued collaborative efforts among industry and regulators will be essential to streamline development and realize patient-centric high-dose SC options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsDrug Delivery SystemsHumansInjections, SubcutaneousAnimalsSuspensionsChemistry, PharmaceuticalDrug Compounding

Stichwörter der Autor:innen

BiologicsHigh-doseLarge-volume subcutaneous administrationSubcutaneousSuspensionsUltra-high concentration

Substanzen

Biological ProductsSuspensions

Autor:innen und Institutionen

  • Pharma Technical Development, Hoffmann-La Roche Ltd, Basel, Switzerland. Electronic address: tarik.khan@roche.com.
  • BioTherapeutics Pharmaceutical Sciences, Pharmaceutical Research and Development, Pfizer, Andover, MA, United States.
  • Process Development Attribute Sciences and Drug Product Technologies, Amgen, Thousand Oaks, CA, United States.
  • Biologics Development, Bristol Myers Squibb, Devens, MA, United States.
  • Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, United States.
  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.

Zitieren

APA

Khan, T. A., Bhattacharya, D., Christian, T. R., Holstein, M., Hua, X., James, R., Jiang, B., Josowitz, A., Laiacona, D., Mehta, S., More, A., Mullen, E., Myers, M., Ricart, B., Rickenbacher, T., Su, Y., & Yaragudi, N. K. R. (2026). High-Dose Subcutaneous Administration of Biologics: Overcoming Barriers Through Formulation and Device Innovation. Advanced Drug Delivery Reviews, 235, 115885. https://doi.org/10.1016/j.addr.2026.115885

Vancouver

Khan TA, Bhattacharya D, Christian TR, Holstein M, Hua X, James R, et al. High-Dose Subcutaneous Administration of Biologics: Overcoming Barriers Through Formulation and Device Innovation. Advanced Drug Delivery Reviews. 2026;235:115885. doi:10.1016/j.addr.2026.115885

BibTeX
@article{Khan2026,
  author = {Khan, Tarik A and Bhattacharya, Deep and Christian, Twinkle R and Holstein, Melissa and Hua, Xiaoqing and James, Roshan and Jiang, Bowen and Josowitz, Alexander and Laiacona, Danielle and Mehta, Shrenik and More, Apurva and Mullen, Edel and Myers, Matthew and Ricart, Brendon and Rickenbacher, Timon and Su, Yongchao and Yaragudi, Naveen Kumar Reddy},
  title = {High-Dose Subcutaneous Administration of Biologics: Overcoming Barriers Through Formulation and Device Innovation},
  journal = {Advanced Drug Delivery Reviews},
  year = {2026},
  volume = {235},
  pages = {115885},
  doi = {10.1016/j.addr.2026.115885}
}
Kostenlos starten →